REGN Regeneron Pharmaceuticals Inc.

Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN

Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN

Commitment builds on Regeneron’s longstanding efforts to develop the STEM talent pipeline as lead sponsor of the premier high school competitions, the Regeneron Science Talent Search (STS) and Regeneron International Science and Engineering Fair (ISEF)

Regeneron will adapt successful initiatives it co-created in its local New York-based community to Nashville’s unique STEM ecosystem, helping to advance students to these premier competitions and inspire STEM careers

Alongside this commitment, Regeneron is participating in Together for CHANGE, a national health and education equity initiative established by Nashville-based Meharry Medical College, further fueling the STEM talent pipeline

TARRYTOWN, N.Y., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a five-year, $5 million strategic investment to bolster Nashville, Tennessee’s science, technology, engineering and mathematics (STEM) ecosystem through high-quality, equitable engagement programs for students and science teachers. Regeneron’s goal is to engage and inspire the next generation of scientific leaders and innovators to help address some of humanity’s most challenging existential threats.

Regeneron will collaborate with the Nashville STEM ecosystem to support existing programs and adapt initiatives that have proven successful in its local New York high school community, as evidenced by student success in the premier high school science competitions. Collaborators will include a number of schools, non-governmental organizations, businesses and universities, including Vanderbilt University’s Collaborative for Science Education and Outreach, Tennessee STEM Innovation Network, Middle Tennessee Science & Engineering Fair, Project Lead The Way, Yonkers Partners In Education, STEM Leadership Center and Society for Science. With its partners, Regeneron will assess Nashville’s current landscape and continuously evolve and adapt its programs for maximum impact on the region's education system.

“I owe my scientific passion and career to programs that got me started when I was in high school – including science research programs and the challenge of the Science Talent Search – which together changed my life and inspired me to pursue science to help cure disease,” said George D. Yancopoulos, M.D., Ph.D., Co-Founder, Co-Chair, President and Chief Scientific Officer of Regeneron. “Among the many STEM programs we support, the ones created in our own backyard of New York over the past decade have proven successful, in part reflected by the success of our local students at the premier high school science competitions. We’re excited to support Nashville in similar ways, and coupled with Together for CHANGE, we hope to unlock and nurture the potential of students, to help promote the next generation of scientific leaders and innovators.”

Regeneron has long-committed to bolstering STEM education at various scales, aiming to encourage more students to pursue careers in these fields and nurture future innovators. The company’s substantial philanthropic commitments include a 10-year, $100 million commitment as the lead sponsor of the Regeneron Science Talent Search (STS), the nation’s oldest and most prestigious pre-college science and mathematics competition, and a five-year, $24 million commitment as lead sponsor of the Regeneron International Science and Engineering Fair (ISEF), the world’s largest high school STEM competition.

In Regeneron’s home state of New York, Regeneron has focused on fostering partnerships with organizations to help strengthen local STEM education and build programs in the area. These initiatives have proven successful in helping students excel in STEM fields and consistently secure placements at these premier competitions. The learnings from this work will be reflected in Regeneron’s commitment to Nashville and evaluated for replication in other cities in the future.

Earlier today, the  (“Together for Changing Healthcare for People of African-Ancestry through an InterNational Genomics & Equity”) initiative was launched in Nashville to address health disparities and promote health in Black communities across the country. A key component of this initiative is to empower educational change by improving the STEM pipeline for Black students. Together for CHANGE is an alliance established by Nashville-based historically Black medical school, Meharry Medical College, and includes the Diaspora Human Genomics Institute and several biopharmaceutical companies, including Regeneron.

Supporting Nashville’s STEM Ecosystem

“At Regeneron, our commitment to STEM education is a holistic endeavor focused on strengthening the entire ecosystem,” said Christina Chan, Senior Vice President, Corporate Affairs at Regeneron. “By supporting Nashville’s science research programs and applying learnings from the programs we have built in New York to Nashville’s unique STEM environment, we hope to enable more students and teachers to engage with and excel in these fields, and to illuminate the many exciting pathways to STEM careers.”

Regeneron’s efforts in Nashville will work to grant teachers research fellowships and professional development opportunities annually, increase student success rates for awards, scholarships, and STEM-centric higher education opportunities, grow the volume of student research projects showcased at science competitions and boost the retention rate of science research teachers.

About Regeneron 

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Regeneron’s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases and rare diseases.

Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the United States. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro-bono and matching gift programs. Our most significant philanthropic commitments are in the area of science education, including the  and .

For additional information about Regeneron, please visit  or follow Regeneron on .

Media Contacts:

Joseph Brown, Regeneron

386-283-1323

 



EN
18/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Regeneron Pharmaceuticals Inc.

 PRESS RELEASE

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spo...

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and...

 PRESS RELEASE

Regeneron Renews Sponsorship of the Regeneron Science Talent Search Th...

Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United States’ oldest and most prestigious science and mathematics competition for high school seniorsSince the start of Regeneron’s sponsorship in 2017 through this year’s STS, Regeneron and the Society have engaged an...

 PRESS RELEASE

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medic...

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS) Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven ...

 PRESS RELEASE

Garetosmab Biologics License Application Accepted for FDA Priority Rev...

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability  If approved, garetosmab would be the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP TARRYTOWN, N.Y., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) toda...

Regeneron Pharmaceuticals Inc: 2 directors

Two Directors at Regeneron Pharmaceuticals Inc sold/sold after exercising options 2,136 shares at between 778.516USD and 778.526USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch